This is an automatically translated article.
Kanausin medicine contains the main ingredient Metoclopramide hydrochloride 10mg and other excipients with just enough drug content provided by the manufacturer. The drug is effective in treating vomiting and nausea.
1. What is Kanausin 10mg?
1.1. Pharmacodynamics of the drug Kanausin 10mg The main drug is Metoclopramide - a blocker of dopamine receptors, antagonizing the central and peripheral effects of dopamine. The antiemetic properties of the drug Metoclopramide are due to its direct anti-dopamine effects on the chemoreceptor trigger zone and the vomiting center as well as the antagonistic effect on serotonin - 5HT3 receptors.
1.2. Pharmacokinetics of the drug Kanausin 10mg Absorption: Metoclopramide is very rapidly absorbed from the gastrointestinal tract. In general, the bioavailability of the drug is about 80%; but depending on the condition and health status of each person because it is related to the way of drug metabolism through the liver. Distribution: Metoclopramide is widely distributed in tissues. The volume of distribution is 2.2-3.4 l/kg. The binding to plasma proteins is very low. Kanausin 10mg can cross the placental barrier and is excreted in breast milk. Metabolism: Metoclopramide is very rarely metabolised. Excretion ability: The drug Kanausin 10mg is eliminated mainly in the urine as unchanged or conjugated with the sulphate group. The mean half-life is about 5 to 6 hours. This time is increased with medical conditions such as liver or kidney failure. 1.3. Indications of the drug Kanausin 10mg Kanausin 10mg is indicated for use in the following cases:
For adults: Prophylaxis of nausea or vomiting that appears late after chemotherapy. Prophylaxis of nausea and vomiting caused by radiation therapy. Treatment of vomiting and nausea, including vomiting and nausea caused by acute migraine. For children from 1 to 18 years of age: As the second-line drug for the prevention of late-onset nausea and vomiting caused by chemotherapy in the treatment of cancers.
2. Usage and dosage of the drug Kanausin 10mg
2.1. How to use the drug Kanausin 10mg Kanausin 10mg drug is prepared in the form of tablets and used orally. Number of times and duration of drug use:
The interval between doses is at least 6 hours. The maximum duration of treatment with Kanausin 10mg is 5 days. If you forget to take a dose, do not take a double dose to make up for the missed dose. 2.2. Dosage of drug Kanausin 10mg For adults: Applicable to all indications:
The recommended therapeutic dose is 10 mg (1 tablet)/time, up to 3 times/day. Maximum recommended dose: 30mg/day or 0.5mg/kg/day. The duration of treatment is 5 days. For children aged 15-18 years and weighing more than 60kg treated, to prevent vomiting and nausea that appear late due to chemotherapy.
Recommended dose is 10 mg (1 tablet)/time, maximum (3 times)/day; or Recommended dose is 0.1-0.15 mg/kg/time, up to 3 times/day. Maximum recommended dose: 30 mg/day or 0.5 mg/kg/day. The duration of treatment is 5 days. Other special subjects:
Elderly: Consider reducing the dose of Kanausin 10mg once based on liver-kidney function and body condition. Renal impairment: Patients with end-stage renal failure (with creatinine clearance ≤15mL/min) should reduce the daily dose by 75%. Patients with severe or moderate renal impairment (with creatinine clearance 15-60mL/min) should reduce the therapeutic dose by 50%. Hepatic impairment: Severe liver failure should reduce the therapeutic dose to 50%. Children: Kanausin 10mg is not recommended for children under 15 years of age and weighing 60kg or less because the dosage form is not suitable. The drug Kanausin 10mg is indicated for the individual with the patient in this special case. Not appropriate in other clinical situations, do not give the drug to others for use
3. Undesirable effects of the drug Kanausin 10mg
When using Kanausin 10mg you may experience unwanted effects (ADRs).
Disorders of hematopoiesis and lymphatic system: Methemoglobin in the blood, possibly due to deficiency of NADH cytochrome 65 reductase, especially in neonates. Sulfhemoglobinemia, caused mainly by use in combination with high doses of sulfur-releasing drugs. Cardiovascular disorders: Uncommon such as bradycardia. Unknown include cardiac arrest, occurring shortly after parenteral administration, possibly following bradycardia, atrioventricular block, sinus arrest, especially when using medicinal products intravenous use; prolongation of the QT interval on the electrocardiogram; torsion apex. Endocrine disorders: Uncommon include amenorrhea, hyperprolactinemia. As rare as increased lactation. Not as obvious as gynecomastia in men. Digestive system disorders: Common as diarrhea, bowel movements many times a day. General disorders and reactions at the injection site such as pain, swelling at the injection site or weakness. Immune system disorders Uncommon such as hypersensitivity. Unknown as anaphylactic reaction. Nervous system disorders Very common, such as drowsiness, drowsiness. Common as extrapyramidal disorders (particularly in children and young adults and/or in overdose, even after a single dose), parkinsonism and restlessness. Uncommon include dystonia, dyskinesia, cognitive impairment. As rare as convulsions, especially in people with a history of seizures. Not known: Tardive dyskinesia may be irreversible, during or after prolonged therapy, especially in the elderly, neuroleptic malignant syndrome. Psychiatric Disorders Common: Psychotic disorder or depression. Uncommon: Hallucinations. Rare: Confusion. Vascular disorders Common: Hypotension, particularly when intravenous preparations are used. Not known: Shock, syncope after injection, acute hypertensive crisis in patients with pheochromocytoma. Endocrine disorders during prolonged treatment with Kanausin 10mg are associated with hyperprolactinemia (amenorrhea, lactation, breast enlargement in men). When experiencing side effects of the drug, you need to stop using Kanausin 10mg and notify the treating doctor or go to the nearest medical facility for timely treatment.
4. Interactions of Kanausin
Combination with contraindications to the drug Kanausin 10mg:
Contraindicated combination of active ingredients Metoclopramide with Levodopa or dopamine agonists due to competitive antagonism. Combinations should be avoided:
Alcoholic beverages such as alcohol can increase the CNS depressant effect of the active ingredient Metoclopramide. Combination to consider:
Because Kanausin 10mg increases gastrointestinal motility, it may change the absorption of some drugs. Anticholinergics and Morphine Derivatives: Anticholinergics and morphine derivatives may have a competitive antagonism with the drug metoclopramide in terms of effects on gastrointestinal motility. Central analgesics (morphine derivatives, anxiolytics, H1-antihistamine tranquilizers, antidepressant tranquilizers, barbiturates, clonidine and related drugs): The combination of central analgesics and Kanausin 10mg may increase psychomotor effects. Sedatives: Kanausin 10mg may increase the effect of neuroleptics and cause extrapyramidal disorders. Serotonergic Drugs: The combination of Kanausin 10mg with serotonergic drugs such as selective serotonin reuptake (SSRI) drugs may increase the risk of serotonin syndrome. Digoxin : Kanausin 10mg may decrease the bioavailability of digoxin. When used in combination, close monitoring of digoxin plasma concentrations is required. Cyclosporin: The drug Kanausin 10mg increased the bioavailability of Cyclosporin (increased Cmax by 46% and increased exposure by 22%). During combination therapy, close monitoring of cyclosporin plasma concentrations is required. The clinical consequences of this interaction are unknown. Strong CYP2D6 Inhibitors
5. Some notes when using the drug Kanausin
Before using Kanausin, you need to carefully read the instructions for use and refer to the information below.
5.1. Contraindications of the drug Kanausin Kanausin 10mg is contraindicated in the following cases:
Hypersensitivity to the drug Metoclopramide or any ingredient of the drug. Gastrointestinal bleeding, mechanical obstruction, or perforation of the gastrointestinal tract due to Kanausin 10mg increases intestinal motility and may make the condition worse. Adrenal myeloma due to the risk of hypertensive crisis. There is a history of metoclopramide- or sedative-induced dyskinesia. Seizures (with increasing frequency and intensity of seizures). People with Parkinson's disease. Use in combination with Levodopa or Dopamine agonists. There is a history of methemoglobinemia due to the use of medicinal products containing Metoclopramide; or lack of NADH cytochorome b5 reductase. Children under 1 year old due to the increased risk of extrapyramidal disorders in this subject. 5.2. Caution in other populations People with renal or hepatic impairment: Dosage reduction is recommended in those with severe renal or hepatic impairment. Ability to drive and use machines: Metoclopramide may cause drowsiness, dizziness, dyskinesia, dystonia and may affect vision and the ability to drive and use machines. of drug users. Pregnancy: The drug metoclopramide is not teratogenic or toxic to the fetus, so it can be used during pregnancy if necessary. Because the pharmacological properties of Metoclopramide are similar to those of other sedatives, the use of the drug in late pregnancy may increase the risk of extrapyramidal syndrome in the child. Therefore, avoid using Kanausin 10mg in late pregnancy; In the case of drug use, it is necessary to closely monitor the manifestations on the newborn. Lactation: Kanausin 10mg is excreted in small amounts into breast milk, so breastfed infants are at risk of adverse drug reactions. Therefore, the use of Kanausin 10mg during lactation is not recommended. In lactating women taking Kanausin 10mg, discontinuation of the drug should be considered. In summary, the drug Kanausin is effective in the treatment of vomiting and nausea. To use the drug safely and to maximize the effectiveness of treatment, patients need to use it exactly as prescribed by the doctor.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
